1. Home
  2. AKRO vs NPO Comparison

AKRO vs NPO Comparison

Compare AKRO & NPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • NPO
  • Stock Information
  • Founded
  • AKRO 2017
  • NPO 2002
  • Country
  • AKRO United States
  • NPO United States
  • Employees
  • AKRO N/A
  • NPO N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • NPO Metal Fabrications
  • Sector
  • AKRO Health Care
  • NPO Industrials
  • Exchange
  • AKRO Nasdaq
  • NPO Nasdaq
  • Market Cap
  • AKRO 3.9B
  • NPO 4.6B
  • IPO Year
  • AKRO 2019
  • NPO N/A
  • Fundamental
  • Price
  • AKRO $45.02
  • NPO $217.33
  • Analyst Decision
  • AKRO Strong Buy
  • NPO Buy
  • Analyst Count
  • AKRO 8
  • NPO 3
  • Target Price
  • AKRO $80.38
  • NPO $223.33
  • AVG Volume (30 Days)
  • AKRO 856.3K
  • NPO 113.1K
  • Earning Date
  • AKRO 08-08-2025
  • NPO 08-05-2025
  • Dividend Yield
  • AKRO N/A
  • NPO 0.58%
  • EPS Growth
  • AKRO N/A
  • NPO 97.53
  • EPS
  • AKRO N/A
  • NPO 3.99
  • Revenue
  • AKRO N/A
  • NPO $1,080,600,000.00
  • Revenue This Year
  • AKRO N/A
  • NPO $7.28
  • Revenue Next Year
  • AKRO N/A
  • NPO $5.60
  • P/E Ratio
  • AKRO N/A
  • NPO $53.78
  • Revenue Growth
  • AKRO N/A
  • NPO 4.99
  • 52 Week Low
  • AKRO $21.34
  • NPO $133.50
  • 52 Week High
  • AKRO $58.40
  • NPO $231.94
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 38.25
  • NPO 48.65
  • Support Level
  • AKRO $43.08
  • NPO $211.28
  • Resistance Level
  • AKRO $46.18
  • NPO $229.34
  • Average True Range (ATR)
  • AKRO 1.62
  • NPO 5.02
  • MACD
  • AKRO -0.30
  • NPO -1.98
  • Stochastic Oscillator
  • AKRO 29.56
  • NPO 29.06

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About NPO Enpro Inc.

Enpro Inc formerly EnPro Industries Inc is a United States-based company that designs, develops, manufactures, and markets proprietary engineered industrial products. The company operates through three segments: Sealing Technologies, which derives maximum revenue, manufactures and markets sealing products, wheel-end components & systems; and Advanced Surface Technologies manufactures wafer processing sub-systems, thin-film coatings, optical filters, and other services like cleaning, coating, testing, and refurbishment. Its geographical segments are the United States, Europe, and other foreign countries.

Share on Social Networks: